Amarantus Bioscience Holdings Inc (AMBS)

[r00kie]

Current Milestones and Catalysts

LymPro
• Pilot clinical performance data (1H-14);
• Retrospective / prognostic 9 year patient record clinical study (1H-14);
• Clinical Performance studies to support CLIA registration (1H-14);
• Commercial Launch as a Laboratory-Developed Test (“LDT”) under CLIA (2H- 2014);

Eltoprazine
• Evaluate best indication for commercial development (1H/14)
• Initiate Phase 2b Clinical Trial (1H/14)

MANF
• Retinitis Pigmentosa: functional genetic mouse model (1H-14)
• Parkinson’s disease: CED delivery data w/Renishaw (1H-14)
• Preliminary systemic toxicology (PK/PD relationship) (1H-14)
• Wolfram Syndrome enablement (Diabetes)

(Above credit goes to Brick for posting)